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Background: The prevalence of asthma has increased over recent decades and the reasons for this are poorly
understood. A sensitive tool that can evaluate potential risk factors for asthma is bronchial hyperresponsiveness
(BHR), a key physiological characteristic of asthma. However, although the minimum clinically important difference
in BHR for an individual is accepted to be around one doubling dose, the minimum important change in a
population is not defined. As with surrogate measures of cardiovascular disease risk such as blood pressure and
cholesterol, a change that is not clinically important in an individual may be extremely important in public health
terms.
Findings: To assess the potential impact of a small absolute change in BHR across a population, we modelled the
effect of different changes in BHR on the prevalence rates of moderate and severe BHR in an asthmatic population.
We calculate that a one half doubling dose increase in BHR increases the prevalence of moderate and severe BHR
by 30%. If this was accompanied by an equivalent increase in the population prevalence of moderate and severe
asthma, this would be highly significant in public health terms.
Conclusions: We propose that a one half doubling dose worsening in BHR across a population may represent an
important change.
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Introduction
The prevalence of asthma and severe asthma has
increased over recent decades and the reasons for this are
poorly understood [1-3]. Large observational studies such
as the ISAAC programme highlight many potential
contributions to the increased rate of asthma including
changes in microbial [4] and parasitic exposure in child-
hood [5], dietary habits [6] and environmental conditions
[4,5], as well as use of medications such as paracetamol
[7-9]. Observational studies cannot prove causality and
randomised controlled trials are better to evaluate the po-
tential role of risk factors in the development of asthma
and its severity. A sensitive tool to assess the effect of* Correspondence: Richard.Beasley@mrinz.ac.nz
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in any medium, provided the original work is ppotential risk factors is bronchial hyperresponsiveness
(BHR), a key underlying physiological characteristic of
asthma [10]. Despite the common use of BHR testing in
clinical trials, the minimum important difference for a
population is not known.
BHR can be assessed through direct or indirect chal-
lenge testing. Although indirect testing may be more
closely related to the degree of airway inflammation, BHR
is most commonly measured through a direct bronchial
challenge test using histamine or methacholine. Direct
bronchial challenge testing is the preferred way of
assessing the effect of medications in clinical trials [11].
With direct BHR the patient is exposed to progressively
greater concentrations of histamine or methacholine, with
each step double the dose or concentration of the previous
one. BHR is then usually expressed in terms of the dose or
concentration required to reduce the forced expiratory
volume in one second (FEV1) by 20% (PD20 or PC20). Ais an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Frequency distribution of asthma severity as
measured by the cumulative dose of histamine which causes a
20% fall in FEV1. The small change in bronchial
hyperresponsiveness (↔) in the population results in a small
increase in the proportion of patients with moderate asthma but a
substantial increase in the proportion with severe asthma.
[Reproduced from Reference [12]].
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nificance for the individual patient, and even undetectable
in view of the natural variability and severity seen in
asthma, may, when applied to the whole population of
patients with asthma, represent a change of major signifi-
cance [Figure 1] [12]. This is analogous to other surrogate
markers of cardiovascular disease risk such as blood pressure
or cholesterol; in which it has been clearly demonstrated that
small changes, which are unlikely to be of significance to an
individual and are smaller than between test variability, can
change the incidence of disease when replicated across a
population. For example it has been suggested that a
2 mmHg reduction in diastolic blood pressure across the
United States population, although unimportant at an indi-
vidual level, would lead to a 6% reduction in coronary heart
disease and 15% reduction in stroke [13].
To assess the potential impact of a small absolute
change in BHR in a population with asthma, we modelledTable 1 Predicted prevalence of severe and moderately sever
from reference [14]]
Doubling dose worsening in
population BHR





0.25 1.15 (1.12-1.17) 4
0.5 1.31 (1.26-1.36) 5
0.75 1.51 (1.42-1.59) 6
1.0 1.73 (1.60-1.86) 7the effect of different changes of BHR on the prevalence
rates of moderate and severe BHR.
Methods
BHR prevalence data was extracted from the report of a
population study by Woolcock and colleagues [14] who
studied the population distribution of BHR, measured as
PD20 to histamine, in a random sample of a rural adult
population. Data was presented on the frequency of BHR,
below a cut-off value for whether BHR was present or not.
The PD20 was calculated as the cumulative dose of hista-
mine causing a 20% fall in FEV1 with ‘cut-off ’ values of
0.1 μmol and 1.0 μmol histamine defining severe and
moderate BHR respectively [14].
Extracted data were plotted as cumulative frequency
versus histamine dose to assess fit with the expected sig-
moid function and then histamine dose was expressed as
logarithm base two, so equal distances between hista-
mine doses represent doubling doses, and the cumula-
tive prevalence was expressed on the natural logarithm
scale. The transformed variables plot was linear and re-
gression was used to estimate the change in cumulative
prevalence of BHR prevalence rates in relation to a
doubling dose change of PD20 (histamine).
Results
The plot of cumulative frequency versus histamine dose
closely resembled the left hand region of a sigmoid curve,
as in the figure. The slope of the line of the transformed
variables relating logarithm cumulative prevalence of BHR
to a doubling dose change of histamine PD20 is 0.55
(95% CI 0.47 to 0.62). By exponentiation this represents a
change in cumulative prevalence rate ratio of 1.73 (95% CI
1.60 to 1.86) per doubling dose change in BHR.
BHR to histamine was present in 10.5% of the popula-
tion in the Woolcock study[14]. Within this group severe
BHR (defined as a PD20 (histamine) ≤0.1 μmol), was pre-
sent in 6.6%, and moderately severe BHR (defined as a
PD20 (histamine) of up to 1.0μmol), was present in 41.2%.
Based on these figures, the changes in prevalence of severe
and moderately severe BHR expected from different doub-
ling dose changes in population BHR are estimated ande BHR with changes in population BHR [Based on data
revalence of moderately severe BHR,
(95% CI)
Prevalence of severe BHR, %
(95% CI)
1.2 6.6
7.3 (46.3-48.1) 7.6 (7.4-7.7)
4.2 (52.1-56.2) 8.7 (8.3-9.0)
2.2 (58.6-65.6) 10.0 (9.4-10.5)
1.4 (65.9-76.6) 11.4 (10.6-12.3)
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BHR increases the prevalence of severe BHR from 6.6% to
8.6% (95% CI 8.3%-9.0%) and moderate to severe BHR
from 41.2% to 54.0% (95% CI 51.9%-56.0%), a relative in-
crease of approximately 30%.
Discussion
Whilst a precise definition of minimum important differ-
ence in BHR for a population is inherently somewhat arbi-
trary, our findings suggest that a one half doubling dose
increase in BHR could significantly alter the prevalence of
severe BHR within a population. Our calculations indicate
that a half doubling dose increase in BHR leads to a 30%
relative increase in the prevalence of severe and moderately
severe BHR, with absolute increases of 2% and 13% re-
spectively. In contrast a quarter doubling dose worsening
in BHR leads to only a minor change, with the 95% confi-
dence interval encompassing a change in the prevalence of
severe BHR of <1%.
A limitation of the interpretation of this analysis is that
an increase in the prevalence of severe BHR cannot be
assumed to lead to an equivalent increase in the preva-
lence of severe asthma. However, increased sensitivity to
bronchial stimuli is one of the fundamental mechanisms
of asthma, [11] increased BHR is associated with more se-
vere asthma [15] and BHR is a recognised outcome meas-
ure reflecting disease activity in asthma [11,16].
If the increases in BHR modelled here result in a simi-
lar increase in the prevalence of moderate to severe
asthma this would be important in public health terms.
In the same way that risk factors such as salt can cause
small changes in blood pressure across a population, it is
possible that small individual changes in BHR caused by
environmental exposure or medication use may lead to
substantial differences in asthma severity across a popu-
lation. We therefore propose that a half doubling dose
worsening in population BHR in response to a risk fac-
tor such as medication use represents an important and
meaningful change.
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